A Phase I, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Subcutaneous Administration of Single Ascending Doses of HRS-5817 in Obese Participants
Latest Information Update: 01 Dec 2025
At a glance
- Drugs HRS 5817 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Atridia
Most Recent Events
- 01 Dec 2025 New trial record